Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes: A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Trial

NCT05949281 is registered in ClinicalTrials.gov with Asger Lund, MD as lead sponsor.

NCT NCT05949281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05949281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes: A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Trial
Lead sponsor
Asger Lund, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 29, 2023
Completion date
January 15, 2031
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, chronic inflammation, type 1 diabetes